Cover Image
市場調查報告書

惡性黑色素瘤的主要20個國家市場的預測:2016-2026年

Malignant Melanoma Forecast in 20 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 361709
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
惡性黑色素瘤的主要20個國家市場的預測:2016-2026年 Malignant Melanoma Forecast in 20 Major Markets 2016-2026
出版日期: 2016年06月30日 內容資訊: 英文 88 Pages
簡介

本報告提供全球主要20個國家市場的惡性黑色素瘤的罹患情形調查,罹患率的變化與預測,各部位、階段、分類的明細,疾病概要,危險因素,疾病診斷與預後,主要的症狀和並存症等彙整資料。

調查對象國家

  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 瑞典
  • 挪威
  • 日本
  • 中國
  • 俄羅斯
  • 澳洲
  • 加拿大
  • 土耳其
  • 南非
  • 沙烏地阿拉伯
  • 韓國
  • 阿根廷
  • 巴西
  • 墨西哥

目錄

  • 簡介
  • 病因
  • 危險因素和預防
  • 疾病診斷
  • 地區/民族的差異
  • 疾病預後和臨床過程
  • 疾病相關的主要並存症/特徵
  • 定量化做患者數的手法
  • 惡性黑色素瘤的罹患率
  • 惡性黑色素瘤的階段、亞形式
    • 階段
    • 部位
    • Clark分類
  • 生物標記與變異
    • 階段III的LDH
    • BRAF變異
    • NRAS變異
  • 治療對象患者估計
    • BRAF+皮膚原發性惡性黑色素瘤
    • BRAF野生型皮膚原發性惡性黑色素瘤
  • 簡稱
  • 相關出版物
  • 線上資料庫
  • 參考文獻
  • 附錄
目錄
Product Code: MGML0010616

image1

Cutaneous Malignant Melanoma is a form of cancer of the skin arising from melanocytes on the external surface of the skin. It can occur anywhere on the body and is more aggressive than the other two forms of skin cancer (basal cell and squamous cell non-melanoma cell skin cancer). Melanoma is the result of a combination of genetic / phenotypic predisposition and environmental catalysts.

This report provides the current incident population for Malignant Melanoma across 20 Major Markets (USA, France, Germany, Italy, Spain, UK, Sweden, Norway, Japan, China, Russia, Australia, Canada, Turkey, South Africa, Saudi Arabia, South Korea, Argentina, Brazil and Mexico) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Malignant Melanoma have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Malignant Melanoma include:

  • Family history of Malignant Melanoma
  • Atypical nevus syndrome
  • Exposure to UV light
  • Skin colour
  • History of Sun burn
  • Cutaneous reaction to sun exposure (freckling, inability to tan, sunburn tendency)
  • >50 common moles

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Malignant Melanoma's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Malignant Melanoma and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Malignant Melanoma's incident population.
  • Identify sub-populations within Malignant Melanoma which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Malignant Melanoma patients.

Coverage

AR, AU, BR, CA, CN, FR, DE, IT, JP, MX, NO, RU, SA, ZA, KR, ES, SE, TR, UK, US

image2

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions associated with the Disease

Methodology for Quantification of Patient Numbers

Top-Line Malignant Melanoma Incidence

Stages and Subtype of Malignant Melanoma

  • Staging of Malignant Melanoma
  • Location of Malignant Melanoma
  • Clark's Subtype of Malignant Melanoma

Biomarkers and Mutations in Malignant Melanoma

  • LDH Status in Stage III Malignant Melanoma
  • BRAF Mutations in Malignant Melanoma
  • NRAS Mutations in Malignant Melanoma

Estimates of Treatment Eligible Malignant Melanoma Patients

  • Treated patients with BRAF+ Cutaneous Malignant Melanoma
  • Treated patients with BRAF wild-type Cutaneous Malignant Melanoma

Abbreviations and Acronyms used in the Report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Figures

  • Increase in cutaneous melanoma incidence by gender in the UK

List of Tables

  • UICC / AJCC Staging for Melanoma
  • Clark's Classification of Melanoma
  • Clark's Subtype of Melanoma
  • Average survival rates for Melanoma by Breslow's thickness
  • Incidence of Malignant Melanoma, total (000s)
  • Incidence of Malignant Melanoma, males (000s)
  • Incidence of Malignant Melanoma, females (000s)
  • AJCC staging in Malignant Melanoma patients, total (000s)
  • AJCC Stage III breakdown for Malignant Melanoma patients, total (000s)
  • Location of Malignant Melanoma, total (000s)
  • Clark's Subtype of Malignant Melanoma, total (000s)
  • LDH Status in Stage III Malignant Melanoma, total (000s)
  • Malignant Melanoma with BRAF mutation, total (000s)
  • BRAF mutation types in Malignant Melanoma patients, total (000s)
  • Acral-Lentiginous Malignant Melanoma with BRAF mutation, total (000s)
  • Malignant Melanoma with NRAS mutation, total (000s)
  • NRAS mutation types in Malignant Melanoma patients, total (000s)
  • Treated Patients by line for Malignant Melanoma, BRAF mutation positive (000s)
  • Treated Patients by line for Malignant Melanoma, BRAF wild-type (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • USA Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • France Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • France Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Germany Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Germany Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Italy Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Italy Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Spain Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Spain Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • United Kingdom Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • United Kingdom Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Turkey Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Turkey Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Russia Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Russia Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Japan Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Japan Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • China Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • China Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • South Korea Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • South Korea Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Sweden Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Sweden Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Norway Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Norway Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Australia Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Australia Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Canada Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Canada Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Argentina Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Argentina Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Brazil Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Brazil Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Mexico Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Mexico Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • South Africa Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • South Africa Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
  • Saudi Arabia Incidence of Malignant Melanoma by 5-yr age cohort, males (000s)
  • Saudi Arabia Incidence of Malignant Melanoma by 5-yr age cohort, females (000s)
Back to Top